Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review

Article information

Clin Mol Hepatol. 2017;23(4):340-346

Publication date (electronic) : 2017 June 20

doi : https://doi.org/10.3350/cmh.2016.0070

Tae Suk Kim¹, Ji Hoon Kim^,1, Baek hui Kim³, Young-Sun Lee², Yang Jae Yoo², Seong Hee Kang², Sang-June Suh², Young Kul Jung², Yeon Seok Seo², Hyung Joon Yim², Jong Eun Yeon², Kwan Soo Byun²

¹Department of Internal Medicine, Kangwon National University School of Medicine, Gangwon, Korea

²Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

³Department of Pathology, Korea University College of Medicine, Seoul, Korea

Corresponding author : Ji Hoon Kim Department of Internal Medicine, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Korea Tel: +82-2-2626-3011, Fax: +82-2626-2024 E-mail: kjhhepar@naver.com

Received 2016 October 20; Revised 2016 December 15; Accepted 2016 December 21.

Abstract

INTRODUCTION

Hepatocelluar carcinoma (HCC) is the fifth most frequent type of malignancy worldwide and is the second most common cause of cancer-related death in the world. Only 30-40% patients with HCC are eligible for potentially curative treatments, such as liver transplantation, surgical resection, radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI). A substantial number of HCC cases are diagnosed at advanced stages, and the median survival following diagnosis is approximately 6 to 20 months [1]. Therapeutic options for patients with late stage HCC at the time of diagnosis include transarterial chemoembolization (TACE) and/or systemic chemotherapy such as sorafenib. Sorafenib (Nexavar^®) is a small molecule that inhibits tumor-cell proliferation and angiogenesis and represents the sole chemotherapeutic agent with proven survival benefit in HCC. Following a successful phase III pivotal trial [2], it has been widely approved around the world for the treatment of advanced HCC. However, sorafenib has not yet been considered as a cytoreductive agents, because the complete response (CR) rate was 0% and partial response rate was only 2.2% (10/449) in two pivotal phase III trial [2,3]. In fact, the objective response rate remains infrequent and CR is extremely rare in real-life practice. Because complete resection is the mainstay for HCC treatment and the only curable option, it is important to investigate methods to improve the resectability of HCC using neoadjuvant therapy. Since 2008, a total of fifteen cases of CR were reported. Moreover, only four cases of CR were confirmed histologically through follow-up surgical resection and only one of these were associated with underlying hepatitis C virus infection with only case having the longest (6 months) recurrence free follow up duration. We present a case of a 54 year old male with underlying hepatitis C virus (HCV) infection who experienced complete histologic remission of his HCC following sorafenib treatment without recurrence after 12 months follow up.

CASE REPORT

A 54-year-old man with HCV (genotype 2a) related liver cirrhosis (LC) presented to our unit due to diffuse abdominal pain. A computed tomography (CT) scan and magnetic resonance imaging(MRI) revealed a 3.8 cm, arterial hypervascular/portal washout mass in the right lobe with invasion of the right portal vein (Fig. 1). Serum alpha-fetoprotein (AFP) level was 12,463 ng/mL. Typical radiographic features with a marked elevation of AFP in HCV-related LC led to the diagnosis of HCC without performing liver biopsy. Further laboratory findings included alanine aminotransferase (ALT) 47 IU/L, total bilirubin 0.49 mg/dL, albumin 3.9 g/dL, PT INR 0.96 and HCV RNA 89,466 IU/mL. The patient had no encephalopathy or ascites. His liver function was well compensated with Child-Pugh A. The patient’s Eastern Cooperative Oncology Group performance status was 1.

Figure 1.

Baseline CT scan showed 3.8 cm sized arterial heterogenously enhancing (A) and delayed wash out (B) hepatic mass. CT scan of portal phase (C) showed right portal vein invasion (arrow)

The patient’s HCC stage based on the Barcelona Liver Cancer Clinic (BCLC) was advanced stage (BCLC C). Therefore, he underwent treatment with sorafenib. Sorafenib therapy was initiated at 400 mg orally, twice daily dosing. The patient tolerated the therapy well with minimal toxicity but did experience grade 2 handfoot skin reaction (HFSR), which was well controlled with ointment and topical analgesics and was not dose limiting. Twelve weeks after beginning therapy, the AFP level was normalized (3.8 ng/mL). In addition, follow-up CT scan showed prominent decrease in hepatic mass with central necrotic changes without any enhancing areas as well as a significant decrease in volume of the right portal vein thrombosis (Fig. 2A, 2B). The tumor response to sorafenib was assessed as complete response by the modified response evaluation criteria in solid tumors criteria [4]. We continued sorafenib therapy to eradicate potentially microscopic tumor cell remnants. After 12 months of sorafenib therapy, the non-enhancing hypodense lesion decreased in size and there was no visible tumor thrombosis in the right portal vein (Fig. 2C, 2D). The patient then underwent right hemihepatectomy with complete resection of the residual tumor.

Figure 2.

Follow up CT scan at 12 weeks after sorafenib Therapy showed significantly decreased mass lesion (A) and portal vein invasion (B, arrow) without arterial enhancement. Follow up CT scan at 12 months after sorafenib Therapy showed more contracted mass lesion (C) and more obliterated portal vein (D, arrow).

Histologic evaluation of the resected hemihepatectomy specimen revealed macrophages and inflammatory cells in a background of fibrinoid necrosis with no viable tumor cells. In the hepatic parenchyma surrounding the mass, chronic hepatitis with fibrosis was observed. There were no viable tumor cells in the thrombosis of the portal vein. Of interest, thrombotic material showed microscopic features similar with the mass lesion (Fig. 3). Because there were no viable tumor cells in the total 14 sections, immunohistochemical staining was not performed. Twelve months after the resection, the patient showed no clinical evidence of recurrence of HCC.

Figure 3.

Gross photo and microscopic features of resected hepatic lesion. (A) Well circumscribed, soft, yellow and lobulated HCC in a background of non-cirrhotic liver. (B) Scanning power view shows fibrinoid necrosis. In the hepatic parenchyma around mass, chronic hepatitis with fibrosis is noted (original magnification ×12.5). (C) No viable tumor cell is observed in the lower power view of the lesion (original magnification ×40). (D, E) Scattered macrophages, Lymphocytes and plasma cells are seen in the fibrinoid necrotic background. Original magnification (D) ×200 and (E) ×400. (F) Low power view shows vascular wall and thrombotic material of portal vein. Thrombotic material shows features similar with the mass lesion. Some macrophages and inflammatory cells with no viable tumor cell in the fibrinoid necrotic material (original magnification ×40).

DISCUSSION

Systemic chemotherapy has not been used primary for patients with advanced HCC because HCC has been considered a relatively chemotherapy resistant tumor. HCC has a high rate of expression of drug resistance genes, such as the heat shock proteins, p-glycoprotein, glutathione-S-transferase, and mutations in p53. Many molecular pathways contribute to HCC carcinogenesis. In addition, outcomes after chemotherapy are significantly influenced by underlying liver dysfunction. Before the sorafenib era, doxorubicin was the mainstay of therapy for advanced HCC refractory to locoregional therapy with approximate response rates of 15-20% [5]. 5-fluorouracil, epirubicin, cisplatin, etoposide, doxorubicin, and their combinations were used in treatment for advanced HCC and the response rate of previous studies have been 13-39% [6]. However, prior to sorafenib, systemic chemotherapy for HCC did not show significant survival benefit compared to placebo in large controlled study. Sorafenib is the first multi kinase inhibitor to be approved by the United States Food and Drug Administration for the treatment of advanced HCC as of 2007. Sorafenib simultaneously inhibits molecular components of the mitogen-activated protein kinase/extracellular-signal-regulated kinase (RAF/MEK/ERK) signaling pathway and platelet-derived growth factor receptor-β/vascular endothelial growth factor receptor (VEGFR) and thereby inhibit tumor growth and inhibit angiogenesis [7]. In the first randomized controlled study, sorafenib treatment was found to reduce the risk of death after one year by 31% and to prolong median survival by approximately three months compared to placebo [2]. Since these discoveries, sorafenib has been regarded as the primary therapeutic strategy for advanced HCC.

However, one of the major drawbacks of sorafenib treatment is the low rate of objective response. Complete surgical resection is the only potentially curative therapy. Therefore, the goal of sorafenib introduction was not only to increase survival time but also to decrease tumor size and the extent to which is resectable for complete elimination of residual lesions. Disappointingly, in two pivotal multicenter phase III placebo-controlled clinical trials of sorafenib for advanced HCC [2,3], no CR was reported in 449 patients who were randomly assigned to sorafenib and only 2% and 3.3% patients were considered as partial responders according to RECIST criteria.

Since the advent of sorafenib for the treatment of advanced HCC, a total of fourteen reports have documented fifteen patients who achieved CR in advanced HCC. However, their clinical findings and courses have been heterogenous (Table 1). The patients have harbored a variety of underlying liver diseases; six with HCV, four patients with hepatitis B virus (HBV), two with alcoholic cirrhosis, two with hereditary hemochromatosis (HHC), and one HBV with human immunodeficiency virus. Most of the patients were male gender, and one Japanese female patient, who had achieved CR with underlying HCV [8]. Among all cases, five HCC cases were confined to the liver, seven cases were intrahepatic HCC with metastasis, and three cases were present in the form of metastatic lesions without an intrahepatic lesion. The fifteen cases of CR included nine cases with oral sorafenib treatment only and six with locoregional treatment or systemic chemotherapy prior to treatment with sorafenib. At the time of diagnosis, four patients were found to have low AFP levels (<400 ng/mL). Among these, two cases had no intrahepatic lesion with metastatic lesions only. Moreover, eleven of the CR cases were evaluated by only radiologic methods, with only four documents of CR supported by imaging, serum tumor marker assessment, and histological examination. Sorafenib treatment time to cessation was 0.4 months up to 22 months. CR was achieved in six months in five cases.

Table 1.

Summary of clinical characteristics and courses of sorafenib induced complete response cases.

Although a total of fifteen cases of CR have been documented worldwide, only four documents were regarded as true CR with adequate assessment methods including imaging, serum tumor marker, and histologic examination of completely resected specimen. Two of these had documented portal vein thrombosis, which is one of main negative prognostic factors of HCC. There were various underlying etiologies and progression of underlying liver disease, including advanced fibrosis (Metavir 3) with HBV, LC with HCV, Alcoholic LC, and advanced fibrosis (Metavir 3) with HHC. Generally, recurrence 2 year after resection has been regarded as de novo, but recurrence within 1-2 year after resection could be accepted as de novo recurrence. Among these cases, the reported follow up duration of two cases were 16 and 6 months, respectively. One HCV-related HCC case with LC did not have portal vein thrombosis. The present report is first case of CR through sorafenib containing histological confirmed, HCV-related HCC without histologic evidence of hepatic cirrhosis, HCC with portal vein thrombosis, and more than 12 months of follow up duration.

In conclusion, this case demonstrates an extremely unusual clinical outcome in advanced HCC. Moreover, the reaction mechanism by which complete histologic response is was achieved remains unclear. Complete histologic response could be demonstrated in rare cases and demonstrates that sorafenib therapy could be a bridge to complete resection in anticipation of a cure for HCC.

Article information Continued